

THE UNITED KINGDOM

One destination for the future of advanced therapy medicine manufacturing

Proven manufacturers. Trusted regulators. World-class science.

Production date – September 2026



Medicines Manufacturing
Industry Partnership

A Thriving Ecosystem for Advanced Therapies



Interlocking strengths position the UK as the manufacturing destination of choice for cell, gene and other advanced therapy developers.

“Science, scale and policy aligned in one nation.”

The UK Life Sciences Sector Plan contains explicit commitments on UK investment in manufacturing innovation



Leadership in Science

Established academic roots, cutting-edge innovation and translational research.

01



Manufacturing Excellence

CDMOs specialising in advanced therapies. Large capacity and skilled workforce.

02



Infrastructure

Strategic location for secure global supply chains and specialist partners.

03



World-Class Regulation

Forward-thinking MHRA alignment, shorter approval routes and accelerated timelines.

04



Government Support & Policy

Advanced Therapies are a key part of the UK's industrial strategy underpinned by strong fiscal incentives and funded translation centres.

05

Manufacturing Excellence

World-class facilities for advanced therapy production

01



Trusted Contract Manufacturing Partners

Robust GMP systems and clear IP protection frameworks



UK GMP ADVANCED-THERAPY
MANUFACTURING CAPABILITY

15,500+ m²

GMP cleanroom footprint for
advanced therapies

32 facilities

Licensed to manufacture advanced therapies

Source: CGT Catapult Manufacturing Survey 2024



Diverse Modalities

Proven track record in viral vectors, cell therapies, gene-edited products, mRNA and other emerging modalities. Science-based regulatory advice available for newer methods.



End-to-end Journey

Established relationships with logistics, QC testing, chain-of-custody/identity systems, and specialist supply-chain partners including cold-chain providers.



Scalable Processes

Full capabilities, from pilot to commercial scale manufacturing. All facilities operate under MHRA-licensed GMP with rigorous quality systems.



Cost-competitive

Attractive cost base, strong VC activity, and a predictable regulatory environment supporting efficient development.



Fast, Flexible Delivery

Adaptive collaboration models, rapid tech transfer, and agile batch scheduling to accelerate clinical timelines.



Regulatory Support

Manufacture within an experienced network of CDMOs, operating under a collaborative and responsive regulator.

UK Contract Manufacturing: Ecosystem Advantage

Facilitates faster time to market



Connected

A network of knowledge and experience

- Direct access to funded campuses and NHS clinical sites linking cutting-edge science, business, and government
- Government funded translation centres, de-risking cutting-edge manufacturing processes
 - [Cell & Gene Therapy Catapult](#)



Technology-Driven

Speed and efficiency

- Digitalisation, automation and single-use technologies with full analytical capability
- Reduces manual steps and operator error, lowering cost per dose and increasing sustainability
- Accelerates batch release timelines
- Technology adoption support through the CGT catapult digital test beds

Source: CGT Catapult Manufacturing Survey 2024



Skills-Based

Experienced, expanding specialist workforce

- 6,200+ employees in operations, trials, testing and logistics
- 2,000+ employees in manufacturing roles
- Talent pool underpinned by national training initiatives such as
 - [RESILIENCE](#) - brings together leading regional training providers to support the UK life sciences workforce by delivering training and outreach, spanning the entire careers pipeline for industry, academia, and the NHS.
 - [Advanced Therapies Apprenticeship Community](#) - the first apprenticeship programme designed specifically to train and upskill individuals in developing, manufacturing and delivering innovative therapies at scale.
 - [Industry Skills Accelerator](#) - a national initiative designed to strengthen the UK's medicines manufacturing workforce. The ISA is building targeted training solutions to meet the evolving needs of this fast-moving sector.

Proven Manufacturing Track Record

Established reputation as a safe, reliable home for advanced therapy manufacturing




200+

Advanced Therapies
manufactured or supported in the UK

UK participates in >50% of all European clinical trials

GLOBAL REACH

UK-manufactured advanced therapies regularly shipped worldwide, including EU, US, China and beyond



Benefitting patients worldwide

Infrastructure & Supply Chain

Strategic locations and connected logistics enabling global advanced therapy distribution.

02



Medicines Manufacturing
Industry Partnership

Robust Global Supply Chains

UK CDMOs ship advanced therapies worldwide - reliably, compliantly, and at competitive speed



Established Global Shipping Routes

- Advanced therapies are shipped from the UK, worldwide
- Starting materials from clinics over the globe are manufactured in the UK



Established Logistics

Network of specialist logistics partners with established shipping routes, experts at handling Advanced Therapies



GMP-Compliant Cold Chain

Specialist cold-chain providers maintaining chain-of-custody, identity systems, and temperature-controlled transport.



Heathrow Hub

Strategic access to Heathrow - connecting the UK to key global markets in competitive transit times.



UK Life Science Manufacturing

Travel times from Heathrow — connecting the UK to the world's leading life science markets



**London
Heathrow**

World's best-connected airport for life science cargo logistics

US
Boston

~7 hrs flight from Heathrow

US
New York

~7 hrs flight from Heathrow

DE
Frankfurt

~2 hrs flight from Heathrow

FR
Paris

~1.5 hrs flight from Heathrow

CH
Zurich

~2 hrs flight from Heathrow

JP
Tokyo

~12 hrs flight from Heathrow

CN
Beijing

~10 hrs flight from Heathrow

AE
Dubai

~7 hrs flight from Heathrow

World-Class Regulation

Globally aligned with accelerated timelines.

03



Medicines Manufacturing
Industry Partnership

Approachable, Globally-aligned Regulator

Medicines and Healthcare products Regulatory Agency (MHRA)



ATMPs manufactured under a regulator committed to providing guidance and safety for innovative manufacturing and therapies



Global Leadership

The UK MHRA is a globally trusted voice on advanced therapy regulation. Currently supporting 49 Phase II/III advanced therapy trials in the UK. World-first CRISPR 9 approval underscores forward-thinking approach to new advanced technologies.

- [Access Consortium](#) - coalition of five national regulatory authorities: Australia's TGA, Health Canada, Singapore's HSA, Swissmedic, and the UK's MHRA
- [ICH](#) member - ICH brings together regulatory authorities and the pharmaceutical industry to discuss the scientific and technical aspects of pharmaceutical development.



Accelerated Timelines

35-day manufacturing licence processing, supported by KPI-driven performance measures and predictable timelines, providing applicants with greater certainty and transparency throughout the approval process.



Innovation-Enabling Regulation

The UK MHRA provide globally aligned scientific guidance for advanced therapy manufacturing, CMC and trial design. Advanced therapy manufacturer's benefit from the regulator that provided the world's first guidance/legislation on point-of-care manufacturing. Advanced therapy developers are supported by a [rare-disease pathway](#), a new regulatory pathway to accelerate the development of treatments.

Supportive Government & Policy

04

Life sciences backed by funding, incentives, and long-term commitment.



Medicines Manufacturing
Industry Partnership

Clear Support from UK Government

Putting innovation in life sciences at the heart of national growth



UK Modern Industrial Strategy

Life sciences is one of the UK's eight growth-driving sectors, with a dedicated sector plan, policy frameworks, and international partnerships. The sector plan holds individuals responsible with clear objectives and targets, with progress published annually.

[uk.gov/industrial-strategy](https://www.uk.gov/industrial-strategy) →

[uk.gov/Life-Sciences-Sector-Plan](https://www.uk.gov/Life-Sciences-Sector-Plan) →

[uk.gov/Life-Sciences-Sector-Plan-Year-One-Update](https://www.uk.gov/Life-Sciences-Sector-Plan-Year-One-Update) →



Investment & Funding

Sustained public and private investment through UKRI, Innovate UK, and dedicated life sciences funding bodies.



Catapult Network

Government-funded translation centres and national innovation campuses drive collaborative R&D and de-risk manufacturing innovation.



International Collaboration

Strategic agreements and global partnerships support market access and cross-border clinical programmes.

Underpinning Fiscal Incentives

Attractive, business-friendly incentives supporting the advanced therapies sector



Up to 27%

R&D Tax Relief

R&D expenditure credit for innovative life science companies

£520 million

Life Sciences Innovative Manufacturing Fund (LSIMF)

£520 million government capital grants to support businesses investing in life science manufacturing projects in the UK

25%

Corporation Tax

One of the lowest rates in the G7 for major economies

10%

Patent Box

Corporation tax rate on profits from patented medicines and innovations

8.6 billion

UK Research and Innovation (UKRI) allocated budget

Record public R&D investment covering financial years 26/27 to 29/30

100%

Capital Allowances

Full expensing for qualifying plant and machinery investments



Medicines Manufacturing Industry Partnership

POWERED BY



About the BIA and ABPI



About the BioIndustry Association (BIA)

BIA is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation.

The BIA has over 600 members spanning human health and non-health biotech, including start-ups, scale-ups and established global companies. Membership also encompasses the full UK ecosystem, including non-commercial research institutions and service providers.

About the Association of the British Pharmaceutical Industry

The ABPI represents companies of all sizes which invest in making and discovering medicines and vaccines to enhance and save the lives of millions of people around the world.

In England, Scotland, Wales and Northern Ireland, the ABPI work in partnership with governments and the NHS so that patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, ABPI members partner with healthcare professionals, academics and patient organisations to find new solutions to unmet health needs.

Slide deck designed by

Victoria Smith
Whitley Marketing & Events